Lexicon Pharmaceuticals Stock (NASDAQ: LXRX)

Lexicon Pharmaceuticals Stock (NASDAQ:LXRX), Trade Ideas

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Earnings Misses

News

Penny Stocks

Health Care

Small Cap

Markets

Trading Ideas

General

LXRX

XOMA

Lexicon Pharmaceuticals (NASDAQ: LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.

Lexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue Estimates

Image22

Movers

COIN

CRML

CSGP

LXEO

MSTR

MTTR

NGVT

RIOT

Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday

Intraday Update

ABTS

AKLI

ALAB

BTOG

BWMN

CISS

CTAS

CZOO

DNUT

DRCT

DXYZ

FRGE

GMDA

JOAN

LIDR

LIXT

LQDA

LUXH

MESO

MRDB

MRVL

NCNO

NCRA

NOAH

NTRB

NUVB

OTRK

OUST

PAVM

PAYS

RDDT

RVYL

SMTC

SNDA

STKS

VERB

XPEV

Shares of  LuxUrban Hotels Inc.  (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates.

Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this drugmaker would post a loss of $0.23 per share when it actually produced a loss of $0.20, delivering a surprise of 13.04%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Lexicon, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.13 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 3.09%. This compares to year-ago revenues of $0.02 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
Lexicon shares have added about 7.8% since the beginning of the year versus the S&amp;P 500&#39;s gain of 5.2%.
What&#39;s Next for Lexicon?
While Lexicon has outperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Lexicon: favorable. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $2.74 million in revenues for the coming quarter and -$0.66 on $24.65 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Xoma (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xoma#NASDAQ">XOMA</a>), has yet to report results for the quarter ended March 2024.
This drug developer is expected to post quarterly loss of $0.71 per share in its upcoming report, which represents a year-over-year change of +27.6%. The consensus EPS estimate for the quarter has been revised 30.6% lower over the last 30 days to the current level.
Xoma&#39;s revenues are expected to be $0.96 million, up 117.1% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2267479/lexicon-pharmaceuticals-lxrx-reports-q1-loss-misses-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2267479">To read this article on Zacks.com click here.</a>

Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 17.65 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $1.130 million which missed the analyst consensus estimate of $1.401 million by 19.33 percent. This is a 4.61K percent increase over sales of $24.000 thousand the same period last year.

Earnings

Lexicon Pharmaceuticals Q1 2024 GAAP EPS $(0.20), Inline, Sales $1.130M Miss $1.401M Estimate

Leerink Partners initiates coverage on Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Outperform rating and announces Price Target of $5.

Price Target

Initiation

Leerink Partners Initiates Coverage On Lexicon Pharmaceuticals with Outperform Rating, Announces Price Target of $5

Management

Lexicon Pharmaceuticals CEO Lonnel Coats Retires

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.
Shares of Matterport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTTR#NASDAQ">MTTR</a>) rose sharply <a href="https://www.benzinga.com/quote/MTTR/news">during Monday's session</a>.
CoStar Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) announced plans to acquire Matterport in a cash and stock transaction valued at $5.50 per share reflecting an estimated $1.6 billion value.
Matterport shares climbed 184% to $4.93 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) surged 27.6% to $8.61. Graphjet Technology&#8217;s Tham Choi Kuen, CFO, announced the decision to resign due to health reasons, effective immediately.</li>
<li>Adlai Nortye Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) gained 12.1% to $13.90.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares climbed 11.2% to $1,305.56 amid a rise in Bitcoin.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) surged 10.4% to $60.79 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $62 to $70.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) climbed 8.7% to $48.30. Jefferies analyst Daniel Rizzo upgraded Ingevity from Hold to Buy and raised the price target from $52 to $62.</li>
<li>KB Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) surged 8.2% to $50.01.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) gained 7.9% to $9.85 amid a rise in Bitcoin.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) climbed 7.9% to $17.31. The Molecular and Clinical Genetics Panel of the U.S. FDA Medical Devices Advisory Committee is scheduled to review the premarket approval application for the company&#8217;s Shield&#x2122; blood test for colorectal cancer (CRC) screening on May 23, 2024.</li>
<li>Lexeo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) rose 6.7% to $12.86 as the company announced a license agreement to accelerate development of LX2006 for the treatment of friedreich ataxia cardiomyopathy.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) gained 6.5% to $1.7550</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) shares rose 6.5% to $224.72 amid a rise in Bitcoin.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) gained 6.2% to $8.60.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) rose 5.4% to $20.60.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/24/04/38356135/wall-streets-most-accurate-analysts-views-on-3-defensive-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Defensive Stocks Delivering High-Dividend Yields</a>

Shares of LuxUrban Hotels Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/luxh#NASDAQ">LUXH</a>) fell sharply during Wednesday&rsquo;s session after the company issued preliminary fourth-quarter <a href="https://www.benzinga.com/quote/LUXH/earnings">revenue outlook below estimates</a>.
LuxUrban said it expects preliminary revenue of $28.2 million for the fourth quarter, versus market estimates of $34.199 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
LuxUrban Hotels shares dipped 27.4% to $1.5523 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>MariaDB plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrdb#NYSE">MRDB</a>) climbed 70.4% to $0.3850 after Progress Software announced that it is possibly considering an offer for the company.</li>
<li>Lixte Biotechnology Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lixt#NASDAQ">LIXT</a>) shares jumped 68.6% to $3.8099 after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100.</li>
<li>Nutriband Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntrb#NASDAQ">NTRB</a>) gained 33.2% to $3.9950 after the company provided a clinical and regulatory path overview for its AVERSA Fentanyl patch.</li>
<li>Verb Technology Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verb#NASDAQ">VERB</a>) surged 30.5% to $0.3656 after the company announced that its MARKET.live entered into a formal partnership with TikTok to become a service provider for TikTok Shop and will receive a TikTok Shop Partner designation.</li>
<li>PaySign, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pays#NASDAQ">PAYS</a>) gained 28.2% to $4.3299 after the company announced better-than-expected fourth-quarter results.</li>
<li>Destiny Tech100 Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) rose 26.6% to $11.39 after gaining 9% on Tuesday.</li>
<li>PAVmed Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pavm#NASDAQ">PAVM</a>) gained 19.7% to $2.4798 after the company issued business update and fourth quarter financial results.</li>
<li>Noah Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/noah#NYSE">NOAH</a>) rose 17.5% to $11.89 after the company reported fourth quarter financial results.</li>
<li>NuScale Power Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smr#NYSE">SMR</a>) rose 17.5% to $4.89.</li>
<li>The ONE Group Hospitality, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stks#NASDAQ">STKS</a>) shares rose 17.2% to $4.70 after the company announced that it will acquire Safflower Holdings.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/djt#NASDAQ">DJT</a>) gained 16.7% to $67.68 after jumping 16% on Tuesday.</li>
<li>Ouster, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oust#NYSE">OUST</a>) gained 16.7% to $5.82 following strong quarterly sales.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) rose 16.3% to $0.4931.</li>
<li>Cazoo Group Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NYSE">CZOO</a>) rose 15.5% to $7.22.</li>
<li>A2Z Smart Technologies Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/az#NASDAQ">AZ</a>) surged 15.3% to $0.5301.</li>
<li>nCino, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncno#NASDAQ">NCNO</a>) gained 15.2% to $34.78 as the company reported better-than-expected fourth-quarter results and issued FY25 adjusted earnings guidance above estimates..</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) climbed 11.6% to $2.22.</li>
<li>Nuvation Bio Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuvb#NASDAQ">NUVB</a>) shares rose 10% to $3.1688. Nuvation Bio shares gained 28% on Tuesday after BTIG upgraded the stock from Neutral to Buy.</li>
<li>Cintas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctas#NASDAQ">CTAS</a>) gained 9.7% to $694.62 after the company reported better-than-expected third-quarter financial results and raised FY24 guidance.</li>
<li>Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) rose 7.8% to $27.12.</li>
<li>Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) gained 5.6% to $72.04.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gamida Cell Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmda#NASDAQ">GMDA</a>) shares fell 83.2% to $0.0575 after the company reported fourth-quarter results and disclosed the commencement of a restructuring process.</li>
<li>Direct Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/drct#NASDAQ">DRCT</a>) dipped 44.8% to $14.60 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Velo3D, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vld#NYSE">VLD</a>) fell 41.2% to $0.3401 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Ryvyl Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvyl#NASDAQ">RVYL</a>) dipped 37.8% to $2.46 following fourth-quarter results.</li>
<li>Forge Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/frge#NYSE">FRGE</a>) fell 26.1% to $1.96 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Organigram Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ogi#NASDAQ">OGI</a>) dipped 22% to $2.08 as the company announced pricing of overnight marketed public offering.</li>
<li>Akili, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akli#NASDAQ">AKLI</a>) shares tumbled 21.2% to $0.3002. The company received a notice of allowance for U.S. Patent Application 17/890,478 titled Cognitive Platform For Deriving Effort Metric For Optimizing Cognitive Treatment (Using Data Computed With Artificial Neural Network Or Deep Learning Techniques).</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) shares fell 19.4% to $3.17. Mesoblast shares jumped over 78% on Tuesday after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease.</li>
<li>X Financial (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xyf#NYSE">XYF</a>) fell 19.2% to $3.7250 following fourth-quarter results.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) fell 18.2% to $0.09 after dipping over 6% on Tuesday. The Nasdaq recently determined that the company is no longer suitable for listing and its stock will be suspended on March 28.</li>
<li>Bit Origin Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btog#NASDAQ">BTOG</a>) fell 18.1% to $4.31.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) fell 17.4% to $0.0397. C3is recently reported a year-over-year increase in fourth-quarter financial results.</li>
<li>AEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lidr#NASDAQ">LIDR</a>) declined 14.6% to $1.34 after the company reported worse-than-expected fourth-quarter revenue results.</li>
<li>GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>) shares fell 14.4% to $13.27 as the company posted weaker-than-expected results for its fourth quarter on Tuesday.</li>
<li>Sonida Senior Living, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snda#NYSE">SNDA</a>) fell 14% to $27.78 following fourth-quarter results.</li>
<li>Nocera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncra#NASDAQ">NCRA</a>) dipped 13.5% to $1.15.</li>
<li>Bowman Consulting Group Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bwmn#NASDAQ">BWMN</a>) fell 11.4% to $34.99 after the company priced a $45 million public offering of common stock at $34 per share.</li>
<li>Reddit, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rddt#NYSE">RDDT</a>) fell 11.3% to $ 57.75.</li>
<li>Krispy Kreme, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnut#NASDAQ">DNUT</a>) fell 10.4% to $15.54.</li>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) fell 10.3% to $0.7001 after gaining 7% on Tuesday.</li>
<li>Astera Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alab#NASDAQ">ALAB</a>) fell 8.8% to $75.99 amid post-IPO volatility.</li>
<li>XPeng Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpev#NYSE">XPEV</a>) declined 8.4% to $7.82.</li>
<li>Liquidia Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>) fell 7% to $14.81.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) fell 5.9% to $4.4959 after the company cut its first-quarter delivery outlook.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/03/37956326/netflix-to-rally-over-15-here-are-10-top-analyst-forecasts-for-wednesday"> Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday </a>

Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.
Shares of Cintas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctas#NASDAQ">CTAS</a>) rose sharply during Wednesday&rsquo;s session after the company reported better-than-expected third-quarter financial results and <a href="https://www.benzinga.com/quote/CTAS/earnings">raised FY24 guidance</a>.
Cintas posted GAAP earnings of $3.84 per share, beating market estimates of $3.59 per share. The company&rsquo;s quarterly sales came in at $2.406 billion, versus expectations of $2.386 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Cintas shares climbed 9.7% to $694.62 on Wednesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>PaySign, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pays#NASDAQ">PAYS</a>) shares jumped 28.2% to $4.3299 after the company announced better-than-expected fourth-quarter results.</li>
<li>Noah Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/noah#NYSE">NOAH</a>) climbed 17.5% to $11.89 after the company reported fourth quarter financial results.</li>
<li>NuScale Power Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smr#NYSE">SMR</a>) gained 17.5% to $4.89.</li>
<li>The ONE Group Hospitality, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stks#NASDAQ">STKS</a>) shares climbed 17.2% to $4.70 after the company announced that it will acquire Safflower Holdings.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/djt#NASDAQ">DJT</a>) climbed 16.7% to $67.68 after jumping 16% on Tuesday.</li>
<li>nCino, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncno#NASDAQ">NCNO</a>) rose 15.2% to $34.78 as the company reported better-than-expected fourth-quarter results and issued FY25 adjusted earnings guidance above estimates..</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) gained 11.6% to $2.22.</li>
<li>Nuvation Bio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nuvb#NYSE">NUVB</a>) rose 11.3% to $3.2050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $1.40 to $10.</li>
<li>Annexon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/annx#NASDAQ">ANNX</a>) gained 10.6% to $7.61 following quarterly results.</li>
<li>NovoCure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvcr#NASDAQ">NVCR</a>) gained 8.6% to $14.19 after the company&#39;s METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial progression for brain metastases from non-small cell lung cancer.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akba#NASDAQ">AKBA</a>) gained 8% to $2.16.</li>
<li>Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) shares gained 7.8% to $27.12.</li>
<li>Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) rose 5.6% to $72.04.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) gained 5.6% to $3.8650.</li>
<li>Wayfair Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/w#NYSE">W</a>) rose 5.4% to $68.27.</li>
<li>Merck &amp; Co., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>) gained 4.4% to $131.09 after the company received FDA approval for Winrevair (sotatercept) for adults with pulmonary arterial hypertension.</li>
<li>Kohl&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kss#NYSE">KSS</a>) rose 4.1% to $27.36.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37956686/top-3-consumer-stocks-that-may-rocket-higher-this-quarter"> Top 3 Consumer Stocks That May Rocket Higher This Quarter</a>

AKBA

ANNX

NVCR

Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday

<a href="https://www.globenewswire.com/Tracker?data=cpH3-j8GJTEQ2tU9d0h3UXLoCu8IzHaG-1dix92k6g-8f6syQX4NU6A84nVCJr1ij2DsQQ5GjtXVp-zBQX9acAb0FEc-0lYOAWob0ZA7SGU=">Lexicon Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American College of Cardiology 73rd Annual Scientific Session &amp; Expo being held April 6 - 8, 2024 in Atlanta, Georgia, including results from a post-hoc evaluation of the efficacy of sotagliflozin in reducing stroke events in patients with type 2 diabetes, chronic kidney disease (CKD), and high cardiovascular (CV) risk in the SCORED Phase 3 clinical trial.
"Following FDA's 2023 approval of INPEFA&#xAE; (sotagliflozin) for heart failure (HF), researchers are adding to the overall scientific understanding of sotagliflozin, including clinical evidence of its ability to reduce the risk of stroke and myocardial infarction (MI), or heart attack," said Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer.
Details of the presentations are as follows:
<ul>
<li>Sotagliflozin Reduces Stroke Outcomes in Patients with Diabetes and Chronic Kidney Disease – a moderated poster presentation, Monday, April 8, 12:15 - 12:25 p.m. ET, Theater 8‚ presented by Rahul Aggarwal, M.D., Icahn School of Medicine at Mount Sinai, New York, New York Study researchers evaluated the efficacy of sotagliflozin in reducing all-cause and cause-specific stroke outcomes among patients with type 2 diabetes, CKD, and high CV risk. In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 (13.6%) fatal events. Sotagliflozin reduced the risk of all-cause stroke by 34%, with 1.2 events per 100 patient-years in the sotagliflozin group and 1.8 events per 100 patient-years in the placebo group. Similarly, sotagliflozin reduced the risk of ischemic stroke by 32%, with 0.8 events per 100 patient-years in the sotagliflozin group and 1.2 events per 100 patient-years in the placebo group. Click <a href="https://www.abstractsonline.com/pp8/?_gl=1&#x2A;155knoh&#x2A;_ga&#x2A;MTY4NTc5NTE4NC4xNzEwNDQ0MjQz&#x2A;_ga_2V8VW4Y237&#x2A;MTcxMTM2ODE2NS40LjEuMTcxMTM2ODMxMi41OS4wLjA.#!/10973/presentation/12628">here</a> to access additional study details in the online abstract.</li>
</ul>
&nbsp;
<ul>
<li>Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Modulated Expression of Glucose Transport and Inflammatory Proteins in Endothelial Cells following Angiotensin II Stimulation – a poster presentation, Sunday, April 7, 1:15 – 2:00 p.m. ET, 1425-157, Hall B4-5, presented by Preston Mason, Ph.D. MBA, Elucida Research, Beverly, Massachusetts Study researchers found that sotagliflozin modulated expression of proteins linked to the Akt signaling pathway, glucose transport and vasodilation in human endothelial cells&nbsp;&nbsp; exposed to an inflammatory stimulus in vitro. The favorable endothelial cell actions of sotagliflozin during inflammation add to the body of knowledge of sotagliflozin's mechanism of action and are consistent with the reduced atherothrombotic risk demonstrated in outcome trials. Click <a href="https://www.abstractsonline.com/pp8/?_gl=1&#x2A;q7x89v&#x2A;_ga&#x2A;MTY4NTc5NTE4NC4xNzEwNDQ0MjQz&#x2A;_ga_2V8VW4Y237&#x2A;MTcxMTM2ODE2NS40LjEuMTcxMTM2ODMxMi41OS4wLjA.#!/10973/presentation/21600">here</a> to access additional study details in the online abstract.</li>
</ul>
&nbsp;
<ul>
<li>Sotagliflozin, a First-in-Class SGLT1/2 Inhibitor, Inhibits Clotting Potential in the Vessel via Inhibition of Platelet Activation, Integrin Activation, and Aggregation in Human Platelets – a moderated poster presentation, Sunday, April 7, 11:30 - 2:40 a.m. ET, Theater 5‚ presented by Livia Stanger, Ph.D. Candidate, University of Michigan, Ann Arbor, Michigan Study researchers found that sotagliflozin inhibits platelet activation through simultaneously targeting SGLT1 and SGLT2. These findings provide insight into the potential mechanism by which sotagliflozin impacts stroke and MI risk in patients with type 2 diabetes and CKD and provides a basis for further studies to explore the role of sotagliflozin for CV protection in patients at increased risk for ischemic events. Click <a href="https://www.abstractsonline.com/pp8/?_gl=1&#x2A;q7x89v&#x2A;_ga&#x2A;MTY4NTc5NTE4NC4xNzEwNDQ0MjQz&#x2A;_ga_2V8VW4Y237&#x2A;MTcxMTM2ODE2NS40LjEuMTcxMTM2ODMxMi41OS4wLjA.#!/10973/presentation/11247">here</a> to access study details in the online abstract.</li>
</ul>
&nbsp;
<ul>
<li>Temporal Shift in Heart Failure Medications Prescribed to Hospitalized Patients According to Sex and Age. Results from Two Large US Integrated Health Systems – a poster presentation, Sunday, April 7, 9:15 – 10:00 a.m. ET, 1343-121, Hall B4-5, presented by Mario Enrico Canonico, M.D., Ph.D., CPC Clinical Research, University of Colorado, Aurora, Colorado Study researchers found that substantial opportunity exists to further improve the prescription of guideline-directed medical therapy (GDMT) for patients with HF. Differences in timing of initiation of these therapies by sex and age highlight the need to evaluate care gaps by these and other determinants of health. Click <a href="https://www.abstractsonline.com/pp8/?_gl=1&#x2A;q7x89v&#x2A;_ga&#x2A;MTY4NTc5NTE4NC4xNzEwNDQ0MjQz&#x2A;_ga_2V8VW4Y237&#x2A;MTcxMTM2ODE2NS40LjEuMTcxMTM2ODMxMi41OS4wLjA.#!/10973/session/1071">here</a> to access additional study details in the online abstract.</li>
</ul>
&nbsp;
On May 26, 2023, the U.S. Food and Drug Administration approved INPEFA&#xAE; (sotagliflozin), a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:
<ul>
<li>heart failure or 
<ul>
<li>type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. &nbsp;</li>
</ul>
</li>
</ul>

Biotech

Events

Lexicon Pharmaceuticals Announces Clinical Data On The Impact Of Sotagliflozin On Stroke And Heart Attack Risk Among Four Lexicon-Sponsored Presentations At The American College Of Cardiology 73rd Annual Scientific Session & Expo

<a href="https://www.globenewswire.com/Tracker?data=sW6NiOPb42Hj781tBvy57iKfF2zE4nIaFwpa-57HBj9Eu7tA4gUbF4X3BOUHcJwAjVGawx8a7KmJ-REOR4NMi3zcJEND8VSOK9bZolKmONQ=" target="_blank">Lexicon Pharmaceuticals, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD). In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort. 
&nbsp;
The efficacy and safety data were presented last week at ATTD 2024 - 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy.
Using data from the 24-week, multinational, placebo-controlled trial, the effects of sotagliflozin 400 mg daily added to insulin therapy on A1C, body weight, systolic blood pressure, eGFR, total insulin dose, adjudicated severe hypoglycemia and DKA were evaluated in a subgroup of patients (228 [16.3%] of 1402]) with type 1 diabetes and CKD (eGFR &lt;60 mL/min/1.73 m2&nbsp;and/or UACR &ge;30 mg/g).
Relative to placebo, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts. Sotagliflozin was associated with similar risks of severe hypoglycemia between the two cohorts.
&quot;Our research team concluded that in patients with type 1 diabetes and CKD, treatment with sotagliflozin had similar A1C, body weight and systolic blood pressure lowering effects as compared to its effect on the total cohort&quot; said David Z.I. Cherney, M.D., Ph. D., Professor in the Department of Medicine at the University of Toronto, and a contributing author of the abstract presented March 7, 2024, at ATTD.
&quot;This research adds important data to the body of evidence supporting our plans to resubmit our New Drug Application for sotagliflozin as an adjunct to insulin therapy in people with type 1 diabetes and CKD,&quot; said Craig Granowitz, M.D., Ph.D., Lexicon&#39;s senior vice president and chief medical officer. &quot;We are optimistic that sotagliflozin may become an important new treatment option for this important population.&quot;

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis Of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment In Patients With Type 1 Diabetes And Chronic Kidney Disease

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday.
Shares of ACADIA Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acad#NASDAQ">ACAD</a>) fell sharply in today&rsquo;s pre-market trading after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not <a href="https://www.benzinga.com/quote/ACAD/news">meet the primary endpoint</a>.
ACADIA Pharmaceuticals shares dipped 17.4% to $19.93 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Power &amp; Digital Infrastructure Acquisition II Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xpdb#NASDAQ">XPDB</a>) shares tumbled 12.6% to $25.57 in pre-market trading after surging 181% on Monday.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) shares fell 5.9% to $9.16 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Aeva Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeva#NASDAQ">AEVA</a>) shares declined 5.4% to $1.23 in pre-market trading. Aeva said it expects a 1-for-5 reverse stock split of its outstanding shares of common stock will be effective as of March 18, 2024.</li>
<li>PLDT Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phi#NYSE">PHI</a>) fell 3.8% to $25.95 in pre-market trading after jumping over 16% on Monday.</li>
<li>NextNav Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nn#NASDAQ">NN</a>) declined 3.6% to $5.07 in pre-market trading. NextNav shares jumped 35% on Monday after the company announced it signed an agreement to acquire spectrum licenses covering an additional 4 MHz in the lower 900 MHz band.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) shares fell 3.2% to $2.72 in pre-market trading. Lexicon shares surged over 29% on Monday after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.</li>
<li>Asana, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/asan#NYSE">ASAN</a>) shares fell 2.4% to $18.35 in pre-market trading following fourth-quarter results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/03/37584146/top-5-risk-off-stocks-that-may-plunge-this-quarter"> Top 5 Risk Off Stocks That May Plunge This Quarter </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Pre-Market Outlook

ACAD

AEVA

ASAN

ASNA

OCUL

XPDB

ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning higher on Monday.
The Dow traded up 0.08% to 38,753.49&nbsp;while the NASDAQ fell 0.20% to 16,052.34. The S&amp;P 500 also fell, dropping, 0.14% to 5,116.66.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37578817/cramer-says-this-healthcare-stock-can-go-higher-calls-manhattan-associates-a-winner"> Cramer Says This Healthcare Stock Can Go Higher, Calls Manhattan Associates &#39;A Winner&#39;</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Materials shares jumped by 0.9% on Monday.
In trading on Monday, industrials shares fell by 0.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
EQT Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eqt#NYSE">EQT</a>) announced that it entered into a definitive merger agreement to acquire Equitrans Midstream Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/etrn#NYSE">ETRN</a>).
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
GDS Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gds#NASDAQ">GDS</a>) shares shot up 22% to $7.80 following a report suggesting Hillhouse and Boyu are in talks to invest in the company&#39;s Southeast Asia data center business.
Shares of Fangdd Network Group Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duo#NASDAQ">DUO</a>) got a boost, surging 20% to $0.7234 after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services <a href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/">sector</a>
Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) shares were also up, gaining 22% to $2.6550 after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Eltek Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eltk#NASDAQ">ELTK</a>) shares dropped 22% to $10.80 after the company announced downbeat quarterly earnings.
Shares of Genie Energy Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gne#NYSE">GNE</a>) were down 10% to $16.98 following fourth-quarter results.
Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) was down, falling 20% to $7.89. Ventyx Biosciences reported clinical data for its NLRP3 inhibitor portfolio and issued pipeline updates at Virtual Investor Event.
Also Check This Out:<a href="https://www.benzinga.com/news/24/03/37584146/top-5-risk-off-stocks-that-may-plunge-this-quarter"> Top 5 Risk Off Stocks That May Plunge This Quarter</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.2% to $77.84 while gold traded up 0.1% at $2,186.40.
Silver traded up 0.6% to $24.69 on Monday while copper rose 0.9% to $3.9275.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.35%, London&rsquo;s FTSE 100 rose 0.12% while Spain&rsquo;s IBEX 35 Index rose 0.19% The German DAX fell 0.38% French CAC 40 fell 0.10% while Italy&rsquo;s FTSE MIB Index fell 0.27%.
Spanish retail trade rose by 0.3% year-over-year in January versus a revised 2.7% gain in the previous month.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Monday, with Japan&rsquo;s Nikkei 225 dipping 2.19%, Hong Kong&rsquo;s Hang Seng Index gaining 1.43%, China&rsquo;s Shanghai Composite Index gaining 0.74% and India&rsquo;s S&amp;P BSE Sensex falling 0.81%.
Chinese vehicle sales dipped by 19.9% year-over-year to 1.58 million units in February versus a 47.9% surge in the prior month. Japanese machine tool orders declined by 8% year-over-year to JPY 114,154 million in February. Japan&#39;s GDP expanded by 0.1% quarter-over-quarter in the fourth quarter versus a 0.8% contraction in the third quarter.
&nbsp;
<h3>Economics</h3>
&nbsp;
No economic report of significance is due for Monday
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37578904/how-to-earn-500-a-month-from-calavo-growers-ahead-of-q1-earnings"> How To Earn $500 A Month From Calavo Growers Ahead Of Q1 Earnings</a>

Eurozone

Commodities

Global

ELTK

ETRN

VTYX

Dow Turns Higher; GDS Holdings Shares Climb

Shares of Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) rose sharply during Monday&rsquo;s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients.
Mesoblast shares jumped 13.4% to $2.4399 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Kidpik Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pik#NASDAQ">PIK</a>) gained 238% to $9.15. Kidpik recently announced a 1-for 5 reverse stock split.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcbp#NASDAQ">TCBP</a>) shares surged 149% to $2.6450.</li>
<li>TRxADE HEALTH, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meds#NASDAQ">MEDS</a>) gained 114.6% to $17.26. TRxADE Health recently announced a special cash dividend of $8 per share.</li>
<li>Fangdd Network Group Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duo#NASDAQ">DUO</a>) shares climbed 108% to $1.2593 after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services <a href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/">sector</a>.</li>
<li>GDS Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gds#NASDAQ">GDS</a>) shares gained 23.7% to $7.93 following a report suggesting Hillhouse and Boyu are in talks to invest in the company&#39;s Southeast Asia data center business.</li>
<li>Solidion Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sti#NASDAQ">STI</a>) rose 23.3% to $0.9620.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kc#NASDAQ">KC</a>) shares gained 23.1% to $3.31. Kingsoft Cloud is expected to report fourth-quarter financial results on March 20, 2024.</li>
<li>EHang Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eh#NASDAQ">EH</a>) gained 21.7% to $13.89. EHang Holdings is expected to release its unaudited financial results for the fourth quarter on March 15, 2024.</li>
<li>Bally&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baly#NYSE">BALY</a>) gained 21.5% to $12.90. Standard General delivered a non-binding letter to the board of directors of Bally&#39;s proposing a transaction under which it would acquire all of the outstanding shares of common stock for $15/share, not currently owned by the company.</li>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) climbed 21.2% to $3.43. Rail Vision received an order from a Class 1 US railroad company for its AI-based safety system.</li>
<li>Marpai, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrai#NASDAQ">MRAI</a>) gained 18.7% to $2.0899.</li>
<li>bioAffinity Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biaf#NASDAQ">BIAF</a>) climbed 18.3% to $1.81.</li>
<li>Lixiang Education Holding Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxeh#NASDAQ">LXEH</a>) gained 15.6% to $4.8797.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) jumped 13.4% to $2.4650 after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.</li>
<li>NWTN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwtn#NASDAQ">NWTN</a>) gained 13.4% to $4.8082.</li>
<li>Pulse Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plse#NASDAQ">PLSE</a>) rose 12.7% to $10.86. Pulse Biosciences announced FDA 510(k) clearance for Cellfx NSPFA Percutaneous Electrode System.</li>
<li>Bilibili Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bili#NASDAQ">BILI</a>) gained 12.7% to $12.55 after JP Morgan upgraded the stock from Underweight to Neutral and raised its price target from $10 to $11. The stock is also gaining amid overall China strength following the annual National People&#39;s Congress event.</li>
<li>Graphite Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grph#NASDAQ">GRPH</a>) climbed 11.7% to $3.5080. Graphite Bio declared a special dividend in connection with proposed merger with Lenz Therapeutics.</li>
<li>STAAR Surgical Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/staa#NASDAQ">STAA</a>) jumped 10% to $39.45 after Stifel upgraded the stock from Hold to Buy and raised its price target from $30 to $50.</li>
<li>VNET Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vnet#NASDAQ">VNET</a>) rose 9.8% to $1.68.</li>
<li>Moderna, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) gained 9.2% to $112.51.</li>
<li>Ituran Location and Control Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/itrn#NASDAQ">ITRN</a>) climbed 7.8% to $28.42.</li>
<li>NuScale Power Corporation(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smr#NYSE">SMR</a>) gained 7% to $5.87. NuScale Power is expected to release fourth quarter results on March 14, 2024.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 4.7% to $1,492.07 amid continued strength in Bitcoin.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jeffs&#39; Brands Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfbr#NASDAQ">JFBR</a>) fell 45.2% to $0.8650.</li>
<li>Eltek Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eltk#NASDAQ">ELTK</a>) shares fell 20.9% to $11.00 after the company announced downbeat quarterly earnings.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cero#NASDAQ">CERO</a>) declined 22% to $3.0822 after jumping 28% on Friday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients.</li>
<li>The Real Good Food Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgf#NASDAQ">RGF</a>) fell 19.7% to $0.5536.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) dipped 18.5% to $8.09. Ventyx Biosciences reported clinical data for its NLRP3 inhibitor portfolio and issued pipeline updates at Virtual Investor Event.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyt#NASDAQ">LYT</a>) fell 15.3% to $6.78 after declining 8% on Friday. Lytus Technologies, last week, announced the launch of Lytus Cloud.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) declined 15.3% to $0.0727.</li>
<li>MoneyLion Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ml#NYSE">ML</a>) fell 15% to $63.36.</li>
<li>Semilux International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/selx#NASDAQ">SELX</a>) fell 14.8% to $1.4403 after jumping 69% on Friday.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyt#NASDAQ">LYT</a>) fell 14.6% to $6.83.</li>
<li>Barnes &amp; Noble Education, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bned#NYSE">BNED</a>) dipped 13.8% to $0.7832. Barnes &amp; Noble Education recently rescheduled its third quarter fiscal year 2024 earnings release.</li>
<li>Psyence Biomedical Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbm#NASDAQ">PBM</a>) fell 13.4% to $1.8272 after jumping 66% on Friday. The company recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study.</li>
<li>Immuron Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrn#NASDAQ">IMRN</a>) shares tumbled 12.5% to $3.3252 after dipping 16% on Friday.</li>
<li>Genie Energy Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gne#NYSE">GNE</a>) fell 12% to $16.67 following fourth-quarter results.</li>
<li>Nanobiotix S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbtx#NASDAQ">NBTX</a>) dipped 9.8% to $6.35.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atxi#NASDAQ">ATXI</a>) fell 8.9% to $0.1749 after surging 10% on Friday.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) dipped 8.8% to $1,039.60.</li>
<li>MannKind Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnkd#NASDAQ">MNKD</a>) declined 8.7% to $4.81. MannKind announced initial meal challenge data from INHALE-3 Phase 4 U.S. trial comparing afrezza head-to-head with multiple daily injections and insulin pumps.</li>
<li>Poseida Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pstx#NASDAQ">PSTX</a>) fell 8.1% to $3.74.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37584162/wall-streets-most-accurate-analysts-say-buy-these-3-energy-stocks-with-over-3-dividend-y"> Wall Street&#39;s Most Accurate Analysts Say Buy These 3 Energy Stocks With Over 3% Dividend Yields</a>

ATXI

BALY

BIAF

BILI

BNED

CERO

EGOX

GRPH

IMRN

ITRN

JFBR

LXEH

MEDS

MNKD

MRAI

MRNA

NBTX

NWTN

PLSE

PSTX

RVSN

SELX

SMCI

STAA

TCBP

VNET

Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping over 50 points on Monday.
The Dow traded down 0.16% to 38,662.09 while the NASDAQ fell 0.26% to 16,043.75. The S&amp;P 500 also fell, dropping, 0.27% to 5,110.11.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37578817/cramer-says-this-healthcare-stock-can-go-higher-calls-manhattan-associates-a-winner"> Cramer Says This Healthcare Stock Can Go Higher, Calls Manhattan Associates &#39;A Winner&#39;</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Materials shares jumped by 0.3% on Monday.
In trading on Monday, industrials shares fell by 1.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
EQT Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eqt#NYSE">EQT</a>) announced that it entered into a definitive merger agreement to acquire Equitrans Midstream Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/etrn#NYSE">ETRN</a>).
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
GDS Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gds#NASDAQ">GDS</a>) shares shot up 21% to $7.77 following a report suggesting Hillhouse and Boyu are in talks to invest in the company&#39;s Southeast Asia data center business.
Shares of Fangdd Network Group Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duo#NASDAQ">DUO</a>) got a boost, surging 48% to $0.8952 after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services <a href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/">sector</a>
Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) shares were also up, gaining 19% to $2.5790 after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Eltek Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eltk#NASDAQ">ELTK</a>) shares dropped 21% to $11.05 after the company announced downbeat quarterly earnings.
Shares of Genie Energy Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gne#NYSE">GNE</a>) were down 11% to $16.93 following fourth-quarter results.
Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) was down, falling 19% to $8.07. Ventyx Biosciences reported clinical data for its NLRP3 inhibitor portfolio and issued pipeline updates at Virtual Investor Event.
Also Check This Out:<a href="https://www.benzinga.com/news/24/03/37584146/top-5-risk-off-stocks-that-may-plunge-this-quarter"> Top 5 Risk Off Stocks That May Plunge This Quarter</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.2% to $78.17 while gold traded up 0.2% at $2,189.80.
Silver traded up 0.3% to $24.615 on Monday while copper rose 0.4% to $3.9085.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.57%, London&rsquo;s FTSE 100 fell 0.30% while Spain&rsquo;s IBEX 35 Index rose 0.10% The German DAX fell 0.63% French CAC 40 fell 0.38% while Italy&rsquo;s FTSE MIB Index fell 0.53%.
Spanish retail trade rose by 0.3% year-over-year in January versus a revised 2.7% gain in the previous month.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Monday, with Japan&rsquo;s Nikkei 225 dipping 2.19%, Hong Kong&rsquo;s Hang Seng Index gaining 1.43%, China&rsquo;s Shanghai Composite Index gaining 0.74% and India&rsquo;s S&amp;P BSE Sensex falling 0.81%.
Chinese vehicle sales dipped by 19.9% year-over-year to 1.58 million units in February versus a 47.9% surge in the prior month. Japanese machine tool orders declined by 8% year-over-year to JPY 114,154 million in February. Japan&#39;s GDP expanded by 0.1% quarter-over-quarter in the fourth quarter versus a 0.8% contraction in the third quarter.
&nbsp;
<h3>Economics</h3>
&nbsp;
No economic report of significance is due for Monday.
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37578904/how-to-earn-500-a-month-from-calavo-growers-ahead-of-q1-earnings"> How To Earn $500 A Month From Calavo Growers Ahead Of Q1 Earnings</a>

Crude Oil Edges Higher; Lexicon Pharmaceuticals Shares Jump

Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) reported its Q4 earnings results on Monday, March 11, 2024 at 07:15 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Lexicon Pharmaceuticals beat estimated earnings by 9.0%, reporting an EPS of $-0.2 versus an estimate of $-0.22.
Revenue was up $674 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 9.0% drop in the share price the next day.
Here's a look at Lexicon Pharmaceuticals's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.17</td>
<td>-0.18</td>
<td>-0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.22</td>
<td>-0.17</td>
<td>-0.16</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.06M</td>
<td>70K</td>
<td>30K</td>
<td>50K</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>162K</td>
<td>317K</td>
<td>24K</td>
<td>28K</td>
</tr>
</tbody>
</table>

To track all earnings releases for Lexicon Pharmaceuticals <a href="https://www.benzinga.com/quote/LXRX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lexicon Pharmaceuticals: Q4 Earnings Insights

WIIM

Lexicon shares are trading higher after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.

Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 25 percent decrease over losses of $(0.16) per share from the same period last year.

Earnings Beats

Lexicon Pharmaceuticals Q4 EPS $(0.20) Beats $(0.22) Estimate, Cash Position $170M

Lexicon Announces Oversubscribed $250M Private Placement Of Equity Securities

Lexicon Pharmaceuticals announces retirement of CEO Lonnel Coats

An announcement from Lexicon Pharmaceuticals (LXRX) is now available. Lonnel Coats has announced his retirement as the CEO and board member of Lexi...

Lexicon Pharmaceuticals CEO Lonnel Coats Announces Retirement

Roanna Ruiz, an analyst from Leerink Partners, has initiated a new Buy rating on Lexicon Pharmaceuticals (LXRX). Roanna Ruiz has given his Buy rati...

Lexicon Pharmaceuticals: A Buy Rating on Strong Market Prospects and Innovative Pipeline

Lexicon Pharmaceuticals Q1 2024 Earnings Preview

Lexicon Pharmaceuticals GAAP EPS of -$0.20 in-line, revenue of $1.13M misses by $0.27M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Lexicon Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lxrx-stock-quote/">LXRX</a>) just reported results for the first quarter of 2024.<ul><li>Lexicon Pharmaceuticals reported earnings per share of -20 cents. This met the analyst estimate for EPS of -20 cents.</li><li>The company reported revenue of $1.13 million.</li><li>This was 17.52% worse than the analyst estimate for revenue of $1.37 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/lxrx-stock-earnings-lexicon-pharmaceuticals-for-q1-of-2024/">LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024

Yigal Nochomovitz, an analyst from Citi, maintained the Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report). The associated price target...

Optimistic Buy Rating for Lexicon Pharmaceuticals Amid Strong Inpefa Sales Outlook and Efficient Financial Management

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company's shares closed yes...

Needham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cigna (CI – Research Report), Lexicon Pharmaceutical...

Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript

IRTC

Press Releases

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

Opinion

Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Lexicon Pharmaceuticals to Host 2024 Investor Day

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024